Skip to content

LSD: all studies

Page 151 of 282: studies 1,501 to 1,510 of 2,815, newest first. Back to the LSD overview

Research

Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program

Journal of Psychoactive Drugs May 18, 2026 Kevin H. Yang, Miranda Rasmussen, Kush V. Bhatt et al. 1 citation

Recent literature suggests potential associations between hallucinogen use and valvular heart disease (VHD) due to prolonged activation of serotonin 5-HT2B receptors, which may lead to valvular fibrosis – a condition also linked to drugs including fenfluramine and pergolide. Despite these concerns, epidemiological studies exploring this association are lacking. This exploratory analysis...

CONTRIBUIÇÕES DOS PSICODÉLICOS PARA A PSICOTERAPIA DA ANSIEDADE: PERSPECTIVAS ATUAIS

ULAKES JOURNAL OF MEDICINE May 13, 2026 Maria Eduarda Marquezi Machioni, Giulia Argueles de Oliveira, Ana Luísa da Silva Rueda et al.

Diante da crescente prevalência dos diagnósticos de transtornos ansiosos no Brasil e no mundo, o presente artigo visa analisar as contribuições das substâncias psicodélicas no tratamento dos transtornos. Por meio de uma revisão narrativa, foram examinados estudos sobre o potencial terapêutico de compostos como LSD, psilocibina, ayahuasca e MDMA. Os resultados colhidos apontam que essas...

DOI: 10.56084/ulakesjmed.v6i1.1495 (opens in new tab) Context archaeology Perspective graphical Subject documents Argument complex analysis +2

Depressions- und Angstsymptome nach psychedelisch-assistierter Psychotherapie bei therapieresistenter Depression: retrospektive Routinedatenanalyse mit vs. ohne komorbide Substanzkonsumstörung

Suchttherapie May 12, 2026 Louise Penzenstadler, Tatiana Aboulafia Brakha, Daniele Zullino

Zusammenfassung Substanzkonsumstörungen (SUD) sind chronische Erkrankungen mit hohen Rückfallraten und begrenzter Wirksamkeit etablierter Behandlungen. Vor diesem Hintergrund rückt die psychedelisch-assistierte Psychotherapie (PAP) mit Psilocybin und LSD zunehmend in den Fokus; die Literatur berichtet Hinweise auf mögliche Effekte insbesondere bei AUD und affektiven Symptomen. Ziel der Studie:...

Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’

Behavioural Pharmacology May 6, 2026 Bart A. Ellenbroek, Gernot Riedel

The past two decades have seen a remarkable renaissance in research on psychedelic drugs and ketamine. Following decades of regulatory restriction that severely limited, especially clinical research, a growing body of evidence has shown that psychedelics such as lysergic acid diethylamide and psilocybin can have long-lasting beneficial effects for treatment-resistant depression, drug and...

DOI: 10.1097/fbp.0000000000000878 (opens in new tab) Ketamine Clinical pharmacology Drug Safety pharmacology +1

Psychoplastogens: What do we know about them?

International Journal of Pharmacology and Clinical Research May 1, 2026 Jyothsna Kuralla, Harsh Chaturvedi

Major depressive disorder (MDD) remains a global health burden, with over 60% of patients failing to respond adequately to current treatments. Treatment-resistant depression (TRD), a form of MDD, highlights the urgent need for mechanistically novel antidepressants. Psychoplastogens—a class of fast-acting compounds that promote neuroplasticity—are emerging as promising alternatives to...

Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms

RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia May 1, 2026 Mariana Silva‐Carvalho, Andreia Machado Brito-Da-Costa, Ricardo Dinis-Oliveira et al.

Psilocybin, psilocin, 5-MeO-DMT, LSD and mescaline are classical hallucinogens whose recreational use has increased over recent decades (Brito-da-Costa et al., 2021; Dinis-Oliveira et al., 2019; Holze et al., 2021; Jiang et al., 2013). However, data on their interactions with cytochrome P450 (CYP450) enzymes remain scarce, despite the potential for clinically relevant drug–drug interactions....

Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.

Drug and Alcohol Dependence May 1, 2026 Juan Carlos C. Montoy, Ralph C. Wang, Allison R. Coker et al.

Psychedelic drug use is increasing due in part to local legislative reforms. Understanding the patterns of first-time psychedelic drug use is imperative for informing consumers, healthcare providers, and policy makers. The National Survey on Drug Use and Health (NSDUH) is a repeated cross-sectional nationally representative survey of civilians aged 12 and older. Use estimates are presented for...

Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.

Journal of Psychopharmacology May 1, 2026 Bonnie Brusky, Katia M'Bailara, François Alla et al.

The nature and role of the psychological support provided in psychedelic-assisted treatments for psychiatric disorders are currently the object of debate. How this support is conceptualized-as a vector for therapeutic change or framework for risk minimization-has far-reaching consequences in terms of how these treatments should be regulated, delivered, and studied. To determine whether...

Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA

AJPM Focus May 1, 2026 R Andrew Yockey, Amber Amis, Elise Devier et al.

AbstractIntroduction Psilocybin, a naturally occurring psychedelic compound found in certain mushroom species, has gained substantial clinical, scientific, and cultural attention in recent years. Despite this growing interest and evolving policy landscape, nationally representative estimates of recent psilocybin use in the United States remain limited. Understanding the current prevalence and...

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal...

DOI: 10.20944/preprints202604.1998.v1 (opens in new tab) Addiction Autism spectrum disorder Hallucinogen Psychopathology +4